Acrivon Therapeutics Launches Phase 1 Cancer Trial, Advances Oncology Pipeline
Company Announcements

Acrivon Therapeutics Launches Phase 1 Cancer Trial, Advances Oncology Pipeline

An update from Acrivon Therapeutics, Inc. ( (ACRV) ) is now available.

Acrivon Therapeutics has initiated a Phase 1 clinical trial for ACR-2316, a novel cancer treatment targeting WEE1/PKMYT1 using their proprietary AP3 platform, with the first patient already dosed. This drug, designed to cause complete tumor regression, has been rapidly advanced to trials, demonstrating the company’s efficient drug discovery process. The trial aims to evaluate the safety, tolerability, and optimal dosage of ACR-2316, with initial results expected in the second half of 2025. Acrivon is also progressing other preclinical programs, leveraging their AP3 platform for precision medicine in oncology.

See more insights into ACRV stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyAcrivon Therapeutics to presents data on deployment of AP3 platform
TheFlyAcrivon announces initial patient dosing in Phase 1 trial of ACR-2316
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App